# A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes

> **NCT06698575** · PHASE1 · COMPLETED · sponsor: **Assembly Biosciences** · enrollment: 103 (actual)

## Conditions studied

- Recurrent Genital Herpes Simplex Type 2

## Interventions

- **DRUG:** ABI-1179
- **DRUG:** ABI-1179 Placebo

## Key facts

- **NCT ID:** NCT06698575
- **Lead sponsor:** Assembly Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-08
- **Primary completion:** 2026-01-19
- **Final completion:** 2026-01-19
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06698575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06698575, "A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06698575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*